MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar
NEWS RELEASE – REGULATED INFORMATION FEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major […]
MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test
NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will […]
MDxHealth Announces Pricing of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin the United States IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering […]
MDxHealth Announces Pricing of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing […]
MDxHealth annonce la détermination du prix de l’offre d’ADSs aux États-Unis
COMMUNIQUÉ DE PRESSE INFORMATION PRIVILÉGIÉE ET RÉGLEMENTÉE 3 FÉVRIER 2023, 8h00 EDT/14h00 CET IRVINE, CA, et HERSTAL, BELGIQUE – 3 février 2023 – MDxHealth SA (NASDAQ/Euronext : MDXH) (“mdxhealth” ou la “Société“), une société spécialisée dans le diagnostic de précision à un stade commercial, a annoncé aujourd’hui avoir fixé le prix d’une offre publique enregistrée […]
MDxHealth annonce le lancement d’une offre d’ADSs aux États-Unis
COMMUNIQUÉ DE PRESSE INFORMATION PRIVILÉGIÉE ET RÉGLEMENTÉE 1 FÉVRIER 2023, 16h00 EDT/22h00 CET IRVINE, CA, et HERSTAL, BELGIQUE – 1 février 2023 – MDxHealth SA (NASDAQ/Euronext : MDXH) (“mdxhealth” ou la “Société“), une société spécialisée dans le diagnostic de précision à un stade commercial, a annoncé le lancement d’une offre proposée de $40.000.000 d’American Depositary […]
MDxHealth Announces Launch of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares (“ADSs“) (each representing 10 ordinary shares of […]
MDxHealth communique des informations financières actualisées et supplémentaires liées à l’acquisition du test GPS
COMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES 19 JANVIER 2023, 1:00 am ET / 07h00 CET IRVINE, CA, et HERSTAL, BELGIQUE – 20 janvier 2023 – MDxHealth SA (NASDAQ/Euronext : MDXH), une société spécialisée dans le diagnostic de précision à un stade commercial, a communiqué aujourd’hui des informations financières supplémentaires relatives à son acquisition du test Oncotype DX® […]
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
NEWS RELEASE –REGULATED INFORMATION 20 JANUARY 2023, 1:00 am ET / 7:00 am CET IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS […]
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance
NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 JANUARY 2023, 4PM ET / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The Company expects to report 2022 revenues of approximately $37 […]
